Breaking Advances
Cancer Res March 1 2011 71 (5) 1509-1510;
Table of Contents
Breaking Advances
Reviews
- ReviewsSuzy V. Torti and Frank M. TortiCancer Res March 1 2011 71 (5) 1511-1514; DOI:10.1158/0008-5472.CAN-10-3614
- ReviewsJoaquín Arribas, José Baselga, Kim Pedersen and Josep Lluís Parra-PalauCancer Res March 1 2011 71 (5) 1515-1519; DOI:10.1158/0008-5472.CAN-10-3795
Priority Reports
- Priority ReportsMarcus Fischer, Wan-Ching Yen, Ann M. Kapoun, Min Wang, Gilbert O'Young, John Lewicki, Austin Gurney and Timothy HoeyCancer Res March 1 2011 71 (5) 1520-1525; DOI:10.1158/0008-5472.CAN-10-2817
Findings provide a preclinical rationale for clinical targeting of a Notch receptor ligand to improve treatment of colon cancers with oncogenic KRAS mutations, which are refractory to existing treatments.
- Priority ReportsXu Wang, Ximei Qian, Jonathan J. Beitler, Zhuo Georgia Chen, Fadlo R. Khuri, Melinda M. Lewis, Hyung Ju C. Shin, Shuming Nie and Dong M. ShinCancer Res March 1 2011 71 (5) 1526-1532; DOI:10.1158/0008-5472.CAN-10-3069
This study reports a rapid, simple and inexpensive assay to detect cancer cells in blood, offering a potentially important tool for clinical management of cancer and cancer relapse.
- Priority ReportsJiali Han, Abrar A. Qureshi, Hongmei Nan, Jiangwen Zhang, Yiqing Song, Qun Guo and David J. HunterCancer Res March 1 2011 71 (5) 1533-1539; DOI:10.1158/0008-5472.CAN-10-1818
A single nucleotide polymorphism identified in a key immune regulatory transcription factor associates with elevated risk of the most common types of skin cancer.
Microenvironment and Immunology
- Microenvironment and Immunology | Free ArticleMélanie Demers, Benoit Ho-Tin-Noé, Daphne Schatzberg, Janie J. Yang and Denisa D. WagnerCancer Res March 1 2011 71 (5) 1540-1549; DOI:10.1158/0008-5472.CAN-10-2038
Depleting platelets in tumor-bearing mice preferentially increases the leakiness of the tumor vasculature, leveraging the efficacy of administered chemotherapies without worsening toxic side-effects.
- Microenvironment and ImmunologyPhilip K. Lim, Sarah A. Bliss, Shyam A. Patel, Marcelo Taborga, Meneka A. Dave, Larissa A. Gregory, Steven J. Greco, Margarette Bryan, Prem S. Patel and Pranela RameshwarCancer Res March 1 2011 71 (5) 1550-1560; DOI:10.1158/0008-5472.CAN-10-2372
Cellular exchange of microRNAs is emerging as a fascinating new mechanism by which tumor stromal cells can influence the tumor cell pathophysiology
- Microenvironment and ImmunologyHolly E. Barker, Joan Chang, Thomas R. Cox, Georgina Lang, Demelza Bird, Monica Nicolau, Holly R. Evans, Alison Gartland and Janine T. ErlerCancer Res March 1 2011 71 (5) 1561-1572; DOI:10.1158/0008-5472.CAN-10-2868
Findings offer preclinical evidence that breast cancer metastasis can be blocked by targeting an important oxidase in the tumor microenvironment.
- Microenvironment and ImmunologyBeverly L. Falcon, Sharon Barr, Prafulla C. Gokhale, Jeyling Chou, Jennifer Fogarty, Philippe Depeille, Mark Miglarese, David M. Epstein and Donald M. McDonaldCancer Res March 1 2011 71 (5) 1573-1583; DOI:10.1158/0008-5472.CAN-10-3126
Small molecule inhibitors now in clinical development to block both mTORC kinases can leverage the anti-angiogenic actions of VEGF inhibitors.
- Microenvironment and ImmunologyPradeep S. Tanwar, LiHua Zhang, Drucilla J. Roberts and Jose M. TeixeiraCancer Res March 1 2011 71 (5) 1584-1596; DOI:10.1158/0008-5472.CAN-10-3166
This interesting mouse model study suggests that tumor suppressor alterations in stromal tissue may be sufficient to drive progression of some types of cancer
- Microenvironment and ImmunologyLoredana Cifaldi, Elisa Lo Monaco, Matteo Forloni, Ezio Giorda, Silvia Lorenzi, Stefania Petrini, Elisa Tremante, Daniela Pende, Franco Locatelli, Patrizio Giacomini and Doriana FruciCancer Res March 1 2011 71 (5) 1597-1606; DOI:10.1158/0008-5472.CAN-10-3326
Findings highlight a novel immunotherapeutic target that is tractable for small molecule inhibition and that could be broadly relevant to many types of human cancer.
- Microenvironment and ImmunologyBruno Salaun, Laurence Zitvogel, Carine Asselin-Paturel, Yannis Morel, Karine Chemin, Clarisse Dubois, Catherine Massacrier, Rosa Conforti, Marie Pierre Chenard, Jean-Christophe Sabourin, Aicha Goubar, Serge Lebecque, Michel Pierres, Donata Rimoldi, Pedro Romero and Fabrice AndreCancer Res March 1 2011 71 (5) 1607-1614; DOI:10.1158/0008-5472.CAN-10-3490
Toll receptors that control innate immune response are not only expressed by immune cells but also by many human cancer cells, which might be targeted directly by Toll receptor agonists in certain disease settings.
- Microenvironment and ImmunologyRomain Bedel, Antoine Thiery-Vuillemin, Camille Grandclement, Jeremy Balland, Jean-Paul Remy-Martin, Bernadette Kantelip, Jean-René Pallandre, Xavier Pivot, Christophe Ferrand, Pierre Tiberghien and Christophe BorgCancer Res March 1 2011 71 (5) 1615-1626; DOI:10.1158/0008-5472.CAN-09-4540
Findings reveal a novel mechanism by which STAT3 modulates immunosurveillance by NK immune cells, by repressing the expression of a key NK cell recognition molecule on cancer cells.
- Microenvironment and ImmunologyEric C. Cheon, Khashayarsha Khazaie, Mohammad W. Khan, Matthew J. Strouch, Seth B. Krantz, Joseph Phillips, Nichole R. Blatner, Laura M. Hix, Ming Zhang, Kristen L. Dennis, Mohammed R. Salabat, Michael Heiferman, Paul J. Grippo, Hidayatullah G. Munshi, Elias Gounaris and David J. BentremCancer Res March 1 2011 71 (5) 1627-1636; DOI:10.1158/0008-5472.CAN-10-1923
“Findings suggest that the established role of arachadonic acid biosynthesis in colon tumorigenesis may be driven to a large degree from mast cells that support myeloid- derived suppressor cells, an important component of the tumor microenvironment thought to drive immune escape.”
- Microenvironment and ImmunologyJonah R. Riddell, Wiam Bshara, Michael T. Moser, Joseph A. Spernyak, Barbara A. Foster and Sandra O. GollnickCancer Res March 1 2011 71 (5) 1637-1646; DOI:10.1158/0008-5472.CAN-10-3674
This study defines a tumor-derived inducer of inflammation that provides an important mechanistic link between chronic inflammation and prostate carcinogenesis.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyFloriane Pez, Frédéric Dayan, Jérome Durivault, Bastien Kaniewski, Géraldine Aimond, Gabrielle S. Le Provost, Blandine Deux, Philippe Clézardin, Pascal Sommer, Jacques Pouysségur and Caroline ReynaudCancer Res March 1 2011 71 (5) 1647-1657; DOI:10.1158/0008-5472.CAN-10-1516
Findings reveal a regulatory cycle that can act synergistically to favor cancer cell proliferation in hypoxic tumor microenvironments.
- Molecular and Cellular PathobiologyShailaja D. Divekar, Geoffrey B. Storchan, Katherine Sperle, David J. Veselik, Earl Johnson, Sivanesan Dakshanamurthy, Yuse N. Lajiminmuhip, Rebecca E. Nakles, Li Huang and Mary Beth MartinCancer Res March 1 2011 71 (5) 1658-1668; DOI:10.1158/0008-5472.CAN-10-1899
Results shed light on a potentially important mechanism involved in estrogen mimicry at the estrogen receptor-alpha, with implications for understanding breast cancer risk and the development of novel therapeutics for treatment of endocrine independent breast cancer.
- Molecular and Cellular PathobiologyRosa Ana Risques, Lisa A. Lai, Cigdem Himmetoglu, Anoosheh Ebaee, Lin Li, Ziding Feng, Mary P. Bronner, Bassel Al-Lahham, Kris V. Kowdley, Keith D. Lindor, Peter S. Rabinovitch and Teresa A. BrentnallCancer Res March 1 2011 71 (5) 1669-1679; DOI:10.1158/0008-5472.CAN-10-1966
In patients with ulcerative coliitis, cell senescence acts as a tumor suppressor mechanism that is abrogated during the transition from low-grade to high-grade dysplasia.
- Molecular and Cellular PathobiologyKouhei Sakurai, Chihiro Furukawa, Takeshi Haraguchi, Ken-ichi Inada, Kazuya Shiogama, Takanobu Tagawa, Shuji Fujita, Yoshihito Ueno, Aya Ogata, Mai Ito, Yutaka Tsutsumi and Hideo IbaCancer Res March 1 2011 71 (5) 1680-1689; DOI:10.1158/0008-5472.CAN-10-2345
Findings describe an microRNA-based mechanism constituting a double feedback loop for control of a pivotal chromatin remodeling factor in cancer cells.
- Molecular and Cellular PathobiologyGuergana Tchakarska, Mikel Roussel, Xavier Troussard and Brigitte SolaCancer Res March 1 2011 71 (5) 1690-1699; DOI:10.1158/0008-5472.CAN-10-2564
Results identify a new function of cyclin D1 that could help explain its important pathophysiological roles in lymphomas and solid tumors.
- Molecular and Cellular PathobiologyTakafumi Suzuki, Jonathan Maher and Masayuki YamamotoCancer Res March 1 2011 71 (5) 1700-1709; DOI:10.1158/0008-5472.CAN-10-2939
“A single-hit mutation in Keap1, a key regulator of the important cytoprotective gene Nrf2, is sufficient to generate a selective advantage in the cancer microenvironment.”
- Molecular and Cellular PathobiologyPippa F. Cosper and Leslie A. LeinwandCancer Res March 1 2011 71 (5) 1710-1720; DOI:10.1158/0008-5472.CAN-10-3145
Findings reveal the mechanisms of cancer-induced cardiac atrophy, which are distinct from skeletal muscle and exhibit sex differences.
- Molecular and Cellular PathobiologyYong Chen, Dongmei Wang, Zhen Guo, Jun Zhao, Bing Wu, Hui Deng, Ti Zhou, Hongjun Xiang, Fei Gao, Xue Yu, Jian Liao, Tarsha Ward, Peng Xia, Chibuzo Emenari, Xia Ding, Winston Thompson, Kelong Ma, Jingde Zhu, Felix Aikhionbare, Kefen Dou, Shi-Yuan Cheng and Xuebiao YaoCancer Res March 1 2011 71 (5) 1721-1729; DOI:10.1158/0008-5472.CAN-09-4683
This study reveals an important mechanistic linkage in metastasis of liver cancers, with potential therapeutic implications.
- Molecular and Cellular PathobiologyChristopher C. Mader, Matthew Oser, Marco A. O. Magalhaes, Jose Javier Bravo-Cordero, John Condeelis, Anthony J. Koleske and Hava Gil-HennCancer Res March 1 2011 71 (5) 1730-1741; DOI:10.1158/0008-5472.CAN-10-1432
Findings define an Abl-related tyrosine kinase in a mechanism of breast cancer invasion that is mediated by invadopodia maturation and function.
- Molecular and Cellular PathobiologyLi Qin, Xian Chen, Yelin Wu, Zhen Feng, Tao He, Li Wang, Lan Liao and Jianming XuCancer Res March 1 2011 71 (5) 1742-1751; DOI:10.1158/0008-5472.CAN-10-3453
Findings suggest a mechanism through which a transcriptional coactivator can promote invasive progression in breast cancers, where it has been implicated as a marker of poor prognosis.
- Molecular and Cellular PathobiologyTao Zuo, Ta-Ming Liu, Xun Lan, Yu-I Weng, Rulong Shen, Fei Gu, Yi-Wen Huang, Sandya Liyanarachchi, Daniel E. Deatherage, Pei-Yin Hsu, Cenny Taslim, Bhuvaneswari Ramaswamy, Charles L. Shapiro, Huey-Jen L. Lin, Alfred S. L. Cheng, Victor X. Jin and Tim H.-M. HuangCancer Res March 1 2011 71 (5) 1752-1762; DOI:10.1158/0008-5472.CAN-10-3573
Combination therapy targeting PI3K/AKT signaling and DNA methylation can effectively reactivate epigenetically silenced genes and slow tumor progression.
Prevention and Epidemiology
- Prevention and EpidemiologyEric J. Jacobs, Christina C. Newton, Michael J. Thun and Susan M. GapsturCancer Res March 1 2011 71 (5) 1763-1771; DOI:10.1158/0008-5472.CAN-10-2953
In this large prospective study, long-term use of cholesterol-lowering drugs was associated with lower risk of melanoma, endometrial cancer, and non-Hodgkin lymphoma.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyIgor Shats, Michael L. Gatza, Jeffrey T. Chang, Seiichi Mori, Jialiang Wang, Jeremy Rich and Joseph R. NevinsCancer Res March 1 2011 71 (5) 1772-1780; DOI:10.1158/0008-5472.CAN-10-1735
Findings suggest strategies for therapeutic targeting of a stem-like phenotype in a relevant cohort of cancer patients.
- Therapeutics, Targets, and Chemical BiologyShinjiro Nagai, Kazumasa Takenaka, Deepa Nachagari, Charles Rose, Kali Domoney, Daxi Sun, Alex Sparreboom and John D. SchuetzCancer Res March 1 2011 71 (5) 1781-1791; DOI:10.1158/0008-5472.CAN-10-1919
Findings show how an cellular efflux transporter can circumvent a major pathway to activate therapeutic nucleoside mimetic drugs.
- Therapeutics, Targets, and Chemical BiologyElvira Avilla, Valentina Guarino, Carla Visciano, Federica Liotti, Maria Svelto, GnanaPrakasam Krishnamoorthy, Renato Franco and Rosa Marina MelilloCancer Res March 1 2011 71 (5) 1792-1804; DOI:10.1158/0008-5472.CAN-10-2186
Findings prompt clinical study of a tractable therapy for thyroid cancer based on disruption of a functionally critical cell surface receptor signaling complex
- Therapeutics, Targets, and Chemical BiologyMunitta Muthana, Athina Giannoudis, Simon D. Scott, Hsin-Yu Fang, Seth B. Coffelt, Fiona J. Morrow, Craig Murdoch, Julian Burton, Neil Cross, Bernard Burke, Roshna Mistry, Freddie Hamdy, Nicola J. Brown, Lindsay Georgopoulos, Peter Hoskin, Magnus Essand, Claire E. Lewis and Norman J. MaitlandCancer Res March 1 2011 71 (5) 1805-1815; DOI:10.1158/0008-5472.CAN-10-2349
Findings describe the use of macrophages to target an oncolytic adenovirus to hypoxic areas of prostate tumors, to improve viral inhibition of primary and secondary tumour growth.
- Therapeutics, Targets, and Chemical BiologyBenjamin J. Moeller, Richard L. Sidman, Renata Pasqualini and Wadih ArapCancer Res March 1 2011 71 (5) 1816-1824; DOI:10.1158/0008-5472.CAN-10-2361
Combinatorial profiling of double-strand DNA break repair machinery yields peptides capable of modulating DNA repair phenotypes and sensitizing tumor cells to genotoxic therapy.
- Therapeutics, Targets, and Chemical BiologyYangzom D. Bhutia, Sau Wai Hung, Bhavi Patel, Dylan Lovin and Rajgopal GovindarajanCancer Res March 1 2011 71 (5) 1825-1835; DOI:10.1158/0008-5472.CAN-10-2736
Findings suggest an effective strategy to defeat chemoresistance in human pancreatic cancers, which remains a primary clinical challenge.
- Therapeutics, Targets, and Chemical BiologySarah A. Martin, Madeleine Hewish, David Sims, Christopher J. Lord and Alan AshworthCancer Res March 1 2011 71 (5) 1836-1848; DOI:10.1158/0008-5472.CAN-10-2836
A kinase originally linked to Parkinson's disease may offer a potential therapeutic target in treatment of cancers characterized by a specific deficiency in DNA repair.
- Therapeutics, Targets, and Chemical BiologyBruce W. Konicek, Jennifer R. Stephens, Ann M. McNulty, Nathaniel Robichaud, Robert B. Peery, Chad A. Dumstorf, Michele S. Dowless, Philip W. Iversen, Stephen Parsons, Karen E. Ellis, Denis J. McCann, Jerry Pelletier, Luc Furic, Jonathan M. Yingling, Louis F. Stancato, Nahum Sonenberg and Jeremy R. GraffCancer Res March 1 2011 71 (5) 1849-1857; DOI:10.1158/0008-5472.CAN-10-3298
Findings offer initial preclinical proof-of-concept for small molecule blockade of a important translational regulator as a tractable cancer therapeutic approach.
- Therapeutics, Targets, and Chemical BiologyAlvin J.X. Lee, David Endesfelder, Andrew J. Rowan, Axel Walther, Nicolai J. Birkbak, P. Andrew Futreal, Julian Downward, Zoltan Szallasi, Ian P.M. Tomlinson, Michael Howell, Maik Kschischo and Charles SwantonCancer Res March 1 2011 71 (5) 1858-1870; DOI:10.1158/0008-5472.CAN-10-3604
Determining the chromosome instability (CIN) status of patient tumors may provide useful information on the clinical response to many cytotoxic agents and small molecules.
- Therapeutics, Targets, and Chemical Biology | Free ArticleRitwik Ghosh, Archana Narasanna, Shizhen Emily Wang, Shuying Liu, Anindita Chakrabarty, Justin M. Balko, Ana María González-Angulo, Gordon B. Mills, Elicia Penuel, John Winslow, Jeff Sperinde, Rajiv Dua, Sailaja Pidaparthi, Ali Mukherjee, Kim Leitzel, Wolfgang J. Kostler, Allan Lipton, Michael Bates and Carlos L. ArteagaCancer Res March 1 2011 71 (5) 1871-1882; DOI:10.1158/0008-5472.CAN-10-1872
Findings suggest that the dimeric state of an oncogenic receptor in cancer cells may impact their therapeutic response to anti-receptor antibodies.
- Therapeutics, Targets, and Chemical BiologyChristina Menke, Lianghua Bin, Jacqueline Thorburn, Kian Behbakht, Heide L. Ford and Andrew ThorburnCancer Res March 1 2011 71 (5) 1883-1892; DOI:10.1158/0008-5472.CAN-10-2252
This study rationalizes anticancer combinations that not only synergize but also overcome drug resistance, a primary challenge in cancer care.
- Therapeutics, Targets, and Chemical BiologyGauri J. Sabnis, Olga Goloubeva, Saranya Chumsri, Nguyen Nguyen, Saraswati Sukumar and Angela M.H. BrodieCancer Res March 1 2011 71 (5) 1893-1903; DOI:10.1158/0008-5472.CAN-10-2458
This incisive and important preclinical study shows how using histone deacetylase inhibtors to restore ER expression in ER-negative tumors can be used to sensitize them to the therapeutic effects of aromatase inhibitors.
- Therapeutics, Targets, and Chemical BiologyBifeng Yuan, Jing Zhang, Hongxia Wang, Lei Xiong, Qian Cai, Tina Wang, Steven Jacobsen, Sriharsa Pradhan and Yinsheng WangCancer Res March 1 2011 71 (5) 1904-1911; DOI:10.1158/0008-5472.CAN-10-3430
“This study reveals a vital mechanistic connection between the widely employed cancer drug 6-thioguanine and its effects on DNA hypomethylation, with implications for understanding therapeutic efficacy.”
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyJeng-Fan Lo, Cheng-Chia Yu, Shih-Hwa Chiou, Chih-Yang Huang, Chia-Ing Jan, Shu-Chun Lin, Chung-Ji Liu, Wen-Yuan Hu and Yau-Hua YuCancer Res March 1 2011 71 (5) 1912-1923; DOI:10.1158/0008-5472.CAN-10-2350
A calcium-binding molecule that is prognostic in several cancers is found to be critical to maintain stemness properties, with implications for new cancer targeting strategies.
- Tumor and Stem Cell BiologyKenichiro Fujiwara, Inez Yuwanita, Daniel P. Hollern and Eran R. AndrechekCancer Res March 1 2011 71 (5) 1924-1932; DOI:10.1158/0008-5472.CAN-10-2386
This study establishes the root causal relationships between Myc and E2F, two key transcription factors involved in virtually all human cancers.
- Tumor and Stem Cell BiologyNiamh E. Buckley, Susan J. Conlon, Karin Jirstrom, Elaine W. Kay, Nyree T. Crawford, Anthony O'Grady, Katherine Sheehan, Simon S. Mc Dade, Ching-Wei Wang, Dennis J. McCance, Patrick G. Johnston, Richard D. Kennedy, D. Paul Harkin and Paul B. MullanCancer Res March 1 2011 71 (5) 1933-1944; DOI:10.1158/0008-5472.CAN-10-2717
Findings define an important transcriptional target of BRCA1 that may provide insight into the pathogenesis of basal-like breast cancers, an aggressive but poorly understood disease.
- Tumor and Stem Cell BiologySilvia Benvenuti, Luca Lazzari, Addolorata Arnesano, Giulia Li Chiavi, Alessandra Gentile and Paolo M. ComoglioCancer Res March 1 2011 71 (5) 1945-1955; DOI:10.1158/0008-5472.CAN-10-2100
Insights into how oncogenic addiction is maintained to the MET kinase, which drives a powerful program of invasive growth in cancer cells, suggests strategies to strengthen cancer therapies based on MET inhibition.
- Tumor and Stem Cell BiologyPäivi Östling, Suvi-Katri Leivonen, Anna Aakula, Pekka Kohonen, Rami Mäkelä, Zandra Hagman, Anders Edsjö, Sara Kangaspeska, Henrik Edgren, Daniel Nicorici, Anders Bjartell, Yvonne Ceder, Merja Perälä and Olli KallioniemiCancer Res March 1 2011 71 (5) 1956-1967; DOI:10.1158/0008-5472.CAN-10-2421
A comprehensive survery defines a set of microRNAs that are important regulators of androgen receptor levels and prostate cancer cell proliferation.
- Tumor and Stem Cell BiologyDenis Jullien, Beatrix Bugler, Christine Dozier, Martine Cazales and Bernard DucommunCancer Res March 1 2011 71 (5) 1968-1977; DOI:10.1158/0008-5472.CAN-10-2453
Findings prompt a rethinking of CDC25B regulation and function and how its impaired expression in cancer may affect susceptibility and chemotherapeutic response.
- Tumor and Stem Cell BiologyHannelore V. Heemers, Lucy J. Schmidt, Zhifu Sun, Kevin M. Regan, S. Keith Anderson, Kelly Duncan, Dan Wang, Song Liu, Karla V. Ballman and Donald J. TindallCancer Res March 1 2011 71 (5) 1978-1988; DOI:10.1158/0008-5472.CAN-10-2512
Findings prompt new insights into how androgen signaling might be selectively blocked in prostate cancer cells while sparing normal androgen-dependent processes.
- Tumor and Stem Cell BiologyRich Y.C. Hsu, Carlos H.F. Chan, Jonathan D. Spicer, Mathieu C. Rousseau, Betty Giannias, Simon Rousseau and Lorenzo E. FerriCancer Res March 1 2011 71 (5) 1989-1998; DOI:10.1158/0008-5472.CAN-10-2833
Infectious complications during colon cancer surgery may contribute to liver metastasis, suggesting benefits to inhibiting these complications during the peri-operative period.
- Tumor and Stem Cell BiologyStuart A. Rushworth, Kristian M. Bowles and David J. MacEwanCancer Res March 1 2011 71 (5) 1999-2009; DOI:10.1158/0008-5472.CAN-10-3018
Findings suggest a strategy to render AML cells sensitive to proteosome inhibitory drugs, which are presently ineffective in this disease.
- Tumor and Stem Cell BiologyZaidoun Salah, Gerry Melino and Rami I. AqeilanCancer Res March 1 2011 71 (5) 2010-2020; DOI:10.1158/0008-5472.CAN-10-3516
A key regulator of the Hippo tumor suppressor pathway functions as a potent oncogene
Corrections
- CorrectionsCancer Res March 1 2011 71 (5) 2021-2021; DOI:10.1158/0008-5472.CAN-11-0067
- CorrectionsCancer Res March 1 2011 71 (5) 2022-2022; DOI:10.1158/0008-5472.CAN-11-0110
- CorrectionsCancer Res March 1 2011 71 (5) 2023-2023; DOI:10.1158/0008-5472.CAN-11-0011
- CorrectionsCancer Res March 1 2011 71 (5) 2024-2024; DOI:10.1158/0008-5472.CAN-11-0122
March 2011
Volume 71, Issue 5
Volume 71, Issue 5
Issue Highlights
Jump to
Advertisement
